Cardiology

The agency granted priority review to dapagliflozin (Farxiga; AstraZeneca) for the treatment of new or worsening chronic kidney disease in adults with and without type 2 diabetes.

Investigators evaluated pharmacogenetic results for statin myopathy risk to determine the clinical benefit of these testing programs.

An FDA panel voted to recommend the expanded use of sacubitril/valsartan (Entresto; Novartis).

Increased prevalence of high blood pressure may be among the “collateral damage” from isolation as a result of the COVID-19 pandemic, investigators said.

“This first-generation polypill is not magic, but it would be clinically worthwhile.”

Of the nearly 3 million Americans included in the study, just 1.4% had the flu vaccine and 1.4% had the pneumonia vaccine.

The meta-analysis accrued data from 18 studies that focused on patients with hospitalized and chronic heart failure.

A key opinion leader discusses the most significant unmet needs in the evolving spectrum of cardiovascular risk management.

Data showed that empagliflozin with standard of care was superior to placebo in reducing the risk of CV death or hospitalization.

A study compared cardiac events associated with azithromycin versus amoxicillin.

The study investigators used artificial intelligence to analyze gut microbiome data in individuals with and without cardiovascular disease.

Approval was based on a phase 3 clinical trial comparing the investigative doses with the approved 1.5 mg dose.

A discussion on recent data updates from the REDUCE-IT trial, and their practical implications for physicians managing cardiovascular risk.

There is no evidence that blood pressure lowering drugs increase the risk of cancer, according to a major new study.

An expert physician discusses the role of agents that reduce triglyceride levels and the potential on cardiovascular risk.

Dapagliflozin (Farxiga; AstraZeneca) demonstrated positive results in the phase 3 DAPA-CKD trial.

A discussion on which factors to consider when assessing the need for management/reduction of cardiovascular risk.

A key opinion leader discusses effective risk prevention measures and challenges to reducing adverse events. He also considers effective educational resources for self-care.

This article reviews the evolving therapeutic landscape for lowering LDL-C and cardiovascular risk, with an emphasis on the role of omega-3 fatty acids.

Empagliflozin (Jardiance; Eli Lilly) met the primary end point of a study for adults with heart failure with reduced ejection fraction with or without diabetes.

Azithromycin may be linked to a greater risk of cardiovascular death, according to a recent study.

A new study found increased plaque buildup levels in women with HIV who also suffered from persistent depression and stress.

Individuals recently diagnosed with type 2 diabetes were more likely to die from heart failure than any other cardiovascular disease, a study found.

This is the first regulatory approval for aspirin plus ticagrelor dual antiplatelet therapy for individuals with high cardiovascular risk but without prior instances of heart attack or stroke.

Researchers from the Mount Sinai COVID Informatics Center report improved survival rates in COVID patients treated with anticoagulants.